Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-07-31
2003-01-07
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S541000, C548S556000, C549S448000, C549S449000, C549S450000, C549S451000, C514S423000
Reexamination Certificate
active
06503940
ABSTRACT:
The invention generally relates to methods for treating infections.
BACKGROUND OF THE INVENTION
A microbial infection such as, for example,
Pneumocystis carinii
pneumonia (PCP), is believed to be one of the leading causes of death in patients suffering from AIDS. Pentamidine [i.e., 1,5-bis(4-amidinophenoxy)pentane] has been used as a therapeutic agent for the treatment of PCP by intravenous infusion and as a prophylactic agent by aerosol dosage, However, the use of this drug may be potentially disadvantageous in that it might be toxic and contribute to hypotension, hypoglycemia, and cardiac arrhythmias experienced by the patient taking pentamidine.
Recent efforts have focused on developing other compounds for potentially treating PCP. A number of aromatic diamidines have displayed potential anti-PCP activity as reported in Boykin D. W., et al.,
J. Med. Chem
., 1995, pp. 912-916; Tidwell, R. R, et al,
Antimicrob. Agents Chemother
. 1993, 37, p. 1713; Lombardy, R. L. et al.,
J. Med. Chem
. 1996, 39, p. 1452; and Kumar, A. et al.,
J. Med. Chem
., 1996, 31, p. 767. Notwithstanding any advantages that these drugs may possess, they may be potentially undesirable since the drugs often exhibit low oral bioavailability.
Chemical modification of drugs into prodrugs can potentially improve physiochemical properties such as water solubility, lipophilicity, transport of drug to the site of action, and presystemic degradation, thus improving oral bioavailability. See Bundgaard, H., In
Design of Prodrugs
; Bundgaard, H.,; Ed.; Elsevier: Amsterdam, The Netherlands, 1985; pp. 1-92; and Bundgaard, H., In
A Textbook of Drug Design and Development
, Krogsgaard-Larsen, P.; Bundgaard, H.; Ed.; Harwood Academic Publ. Switzerland, 1991, pp. 113-191. A number of reports exist on the prodrug modification of carboxyl, hydroxyl, thiols, and amino compounds. See, for example, Friis, G. J., et al., In
A Textbook of Drug Design and Development
, 2
nd
Ed., Krogsgaard-Larsen, P., Liljefors, T. Madsen, U.; Ed.; Overseas Pub: Amsterdam, The Netherlands, 1996, pp. 351-385; Digenis, G. A., et al.,
Drug Iatentiation, Handbook of Experimental Pharmacology
, 1975, 28, pp. 86-112. Moreover, Weller et al. (
J. Med. Chem
., 1996, 39, pp. 3139-3146) propose employing amidoximes and carbamate derivatives of mono-amidines as prodrugs in order to potentially provide improved oral availability for fibrogen antagonists. In addition, Boykin, D. W., et al., (
Bioorg. Med. Chem. Lett
., 1996, 6, pp. 3017-3020) have reported that bis-amidoxime and O-methylamidoxime may be effective anti-PCP agents on both oral and intravenous administration. U.S. Pat. No. 5,723,495 to Hall et al. proposes administering a bis-benzamidoxime to a patient for treating
Pneumocystis carinii.
Notwithstanding the above efforts, there remains a need in the art to provide drugs that display improved activity.
SUMMARY OF THE INVENTION
A method of combating an infection to a subject in need of such a treatment is disclosed. The method comprises administering to the subject a compound of the formula (I):
wherein:
X may be O, S, or NR′ wherein R′ is H or loweralkyl;
R
1
and R
2
may be independently selected from the group consisting of H, loweralkyl, oxyalkyl, alkoxyalkyl, cycloalkyl, aryl, hydroxyalkyl, aminoalkyl, and alkylaminoalkyl;
R
3
and R
4
are each independently selected from the group consisting of H, loweralkyl, halogen, oxyalkyl, oxyaryl, and oxyarylalkyl;
R
5
is represented by a formula selected from the group consisting of:
wherein:
X
1
, X
2
, and X
3
are independently selected from O and S; and
R
6
and R
7
are independently selected from the group consisting of loweralkyl, aryl, alkylaryl, oxyaryl, an ester-containing substituent, and oxyalkyl; or a pharmaceutically acceptable salt thereof, and wherein said compound of Formula (I) is administered in an amount to treat the infection.
Preferably, R
6
and R
7
are independently selected from the group consisting of:
CH
3
, CH
2
CCl
3
, CH
2
CH
3
,
In one preferred embodiment, each of the substituents present on the compound of formula (I) represented by the formula:
are present on the para positions of the aromatic groups on formula (I), although these substituents may be present in the meta positions,
The invention also discloses pharmaceutical compounds represented by the formula (I) described herein and pharmaceutically acceptable salts thereof, as well as pharmaceutical formulations comprising the pharmaceutical compounds of formula (I) and pharmaceutically acceptable carriers.
REFERENCES:
patent: 4748265 (1988-05-01), Oxbol et al.
patent: 5103041 (1992-04-01), A'Court et al.
patent: 5260473 (1993-11-01), McGhee et al.
patent: 5606058 (1997-02-01), Boykin et al.
patent: 5618827 (1997-04-01), Oxford
patent: 5627184 (1997-05-01), Boykin et al.
patent: 5668166 (1997-09-01), Tidwell et al.
patent: 5686456 (1997-11-01), Boykin et al.
patent: 5723495 (1998-03-01), Hall et al.
patent: 5843980 (1998-12-01), Hall et al.
patent: 0051871 (1982-05-01), None
patent: 0142670 (1985-05-01), None
patent: WO 85/05105 (1985-11-01), None
patent: WO 97/17949 (1997-05-01), None
patent: WO 97/23499 (1997-07-01), None
Bundgaard;Design of prodrugs, Elsevier Science Publishers B. V. (Biomedical Division), The Netherlands, ISBN 0-444-80675-X, pp. 1-92 (1985).
Bundgaard et al;A Textbook of Drug Design and Development, Harwood Academic Publishers GmbH, Switzerland, ISBN 3-7186-5099-1,pp. 113-191 (1991).
Friis et al.;A Textbook of Drug Design and Development Second Edition, Harwood Academic Publishers GmbH, The Netherlands, ISBN 3-7186-5866-6, pp. 351-385 (1996).
Adams et al.; “Synthesis and Antitumor Activity of 9-[(Carbamoyloxy)alky1] anthracyclines: A Novel Class of Anthracycline Derivatives,” J. Med. Chem. 33:9 2380-2384 (1990).
Alexander et al.; (Acyloxy)alky1 Carbamate Prodrugs of Norfloxacin,J. Med. Chem. 34:1 78-81 (1991).
Alpegiani et al.; “On the Preparation of 4-Hydroxymethyl-5-Methyl-1, 3-Dioxol-2-One,” Synthetic Communications 22:9 1277-1282 (1992).
Bajic et al.; “Synthesis of 2,5-Bis-(4-Cyanophenyl)-Furan,” 2:135-140 (1996).
Boykin et al.; “Anti-Pneumocystis Activity of Bis-Amidoximes and Bis-O-Alkylamidoximes Prodrugs,”Bioorganic&Medicinal Chemistry Letters 6:24 3017-3020 (1996).
Boykin et al.; “Dicationic Diarylfurans as Anti-Pneumocystis Carinii Agents,”J. Med. Chem. 38 912-916 (1995).
Das et al.; “Synthesis and Antiprotozoal Activity of 2,5-Bis(4-guanylphenyl)furans,”Journal of Medicinal Chemistry20:4 531-536 (1977).
Hetnarski et al.; “Preparation and Properties of Phenyl Carbamates with Phosphoryl and Carbamyl Substituents,”J. Agr. Food Chem.20:3 543-546 (1972).
Koreeda et al.;“A New Reagent for the Selective, High-Yield N-Dealkylation of Tertiary Amines: Improved Syntheses of Naltrexone and Nalbuphine,”J. Org. Chem.49:11 2081-2082 (1984).
Kumar et al.;“Anti-Pneumocystis carinii pneumonia activity of dicationic 2,4-diaryylpyrimidines,”Eur. J. Med. Chem. 31 767-773 (1996).
Kasukawa et al.; “N-(3,4-Methylenedixyphenyl)carbamates as Potent Flower-Inducing Compounds in Asparagus Seedlings as Well as Probes for Binding to Cytocrome P-450,”Z. Naturforsch50:c 373-379 (1995).
Lin et al.; “Mono and Bis Double Ester Prodrugs of Novel Aminomethyl- THF 1-Methylcarbapenems,”Bioorganic&Medicinal Chemistry Letters 7: 14 1811-1816 (1997).
Lombardy et al.; “Synthesis and DNA Interactions of Benzimidazole Dications Which Have Activity against Opportunistic Infections,”J. Med. Chem. 39 1452-1462 (1996).
Millan et al.; “The Dealkylation of Tertiary Aliphatic Amines with Phenyl Chlorothionoformate,”Tetrahedron Letters39 4389-4390 (1998).
Sakamoto et al.; “Studies on Prodrugs. II. Preparation and Characterization of (5-Substituted 2-Oxo-1, 3-dioxolen-4-yl)methyl Esters of Ampicillin,”Chem. Pharm. Bull. 32:6 2241-2248 (1984).
Shridhar et al.; “Synthesis of Some New Carbamates & Amidines Derived from -Amino-3-N,N-disubstitutedamino/heterocyclyl-2H-1,4-behzoaxazines as Possible Anthelmintics,”Indian Journal of Chemistry20:B 1075-1077 (1981).
Thomsen et al.; “Eval
Boykin David W.
Hall James E.
Rahmathullah M. Syed
Tidwell Richard R.
Jenkens & Wilson, P.A.
McKane Joseph K.
Shameem Golam M. M.
The University of North Carolina at Chapel Hill
LandOfFree
Prodrugs for antimicrobial amidines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prodrugs for antimicrobial amidines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prodrugs for antimicrobial amidines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3030396